Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04251572Not ApplicableUnknown

HCV Reinfection After DAA Therapy in PWID in Belgium

Role: collaborator

NCT02887638Not ApplicableCompleted

Headache Analysis and Intervention

Role: collaborator

NCT02024113Completed

LC-NMR Study Biomarkers to Detect Lung Cancer

Role: collaborator

NCT02362776Completed

Metabolic Changes as a Diagnostic Indicator for Cancer

Role: collaborator

NCT02044718Completed

Medical Record Study on Adverse Events Requiring a Higher Level of Care in Flemish Hospitals

Role: collaborator

All 5 trials loaded